{"protocolSection": {"identificationModule": {"nctId": "NCT01397162", "orgStudyIdInfo": {"id": "1248.5"}, "secondaryIdInfos": [{"id": "2010-023167-17", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat\u00ae Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy", "officialTitle": "A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 22.7, 45.5 and 90.9 Doses b.i.d. Administered Via Respimat\u00ae Inhaler and Fluticasone Propionate HFA MDI 88 mcg b.i.d. in Patients With Asthma Inadequately Controlled on SABA Therapy"}, "statusModule": {"statusVerifiedDate": "2022-05", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-07-21", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-12-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-07-18", "studyFirstSubmitQcDate": "2011-07-18", "studyFirstPostDateStruct": {"date": "2011-07-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-04-06", "resultsFirstSubmitQcDate": "2022-05-27", "resultsFirstPostDateStruct": {"date": "2022-06-23", "type": "ACTUAL"}, "dispFirstSubmitDate": "2014-04-30", "dispFirstSubmitQcDate": "2014-04-30", "dispFirstPostDateStruct": {"date": "2014-05-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-05-27", "lastUpdatePostDateStruct": {"date": "2022-06-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.) and fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 88 mcg b.i.d and placebo b.i.d. over an 8-week treatment period in asthmatic patients aged 12 to 65 years inadequately controlled on short-acting-beta-agonist (SABA) prn therapy only as demonstrated by a decrease in forced expiratory volume in one second (FEV1) range10 to 25% and an asthma control questionnaire (ACQ-6) equal or greater than 1.5 at time of randomization"}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 29, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BI 54903 - low dose", "type": "EXPERIMENTAL", "description": "BI 54903 low dose 2 puffs twice daily (b.i.d.) via Respimat inhaler plus hydrofluoralkane (HFA) metered dose inhaler (MDI) matching placebo 2 puffs b.i.d.", "interventionNames": ["Drug: BI 54903"]}, {"label": "BI 54903 - medium dose", "type": "EXPERIMENTAL", "description": "BI 54903 medium dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.", "interventionNames": ["Drug: BI 54903"]}, {"label": "BI 54903 - high dose", "type": "EXPERIMENTAL", "description": "BI 54903 high dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.", "interventionNames": ["Drug: BI 54903"]}, {"label": "Fluticasone propionate", "type": "ACTIVE_COMPARATOR", "description": "Fluticasone propionate 2 puffs twice b.i.d via HFA MDI plus placebo BI 54903 via Respimat inhaler 2 puffs b.i.d.", "interventionNames": ["Drug: Fluticasone propionate"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo Respimat inhaler 2 puffs b.i.d. and placebo HFA MDI, 2 puffs b.i.d.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone propionate", "description": "Fluticasone propionate", "armGroupLabels": ["Fluticasone propionate"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo matching fluticasone propionate HFA MDI", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "BI 54903", "description": "BI 54903", "armGroupLabels": ["BI 54903 - high dose", "BI 54903 - low dose", "BI 54903 - medium dose"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From the Randomisation Baseline to the End of the 8-week Treatment Period in Trough (Morning Pre-dose and Pre-rescue Bronchodilator ) Forced Expiratory Volume in One Second (FEV1)", "description": "Mean change from the randomisation baseline to the end of the 8-week treatment period in trough (morning pre-dose and pre-rescue bronchodilator ) forced expiratory volume in one second (FEV1).", "timeFrame": "At baseline and week 8."}], "secondaryOutcomes": [{"measure": "Mean Changes From Randomisation Baseline in Trough (Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in One Second (FEV1) After 2 and 4-week Treatment Periods", "description": "Mean changes from randomisation baseline in trough (pre-dose and pre-rescue bronchodilator) forced expiratory volume in one second (FEV1) after 2 and 4-week treatment periods.", "timeFrame": "At baseline and at week 2 and 4."}, {"measure": "Mean Changes From Randomisation Baseline in Trough (Pre-dose and Pre-rescue Bronchodilator) Forced Vital Capacity (FVC) After 2, 4 and 8-week Treatment Periods", "description": "Mean changes from randomisation baseline in trough (pre-dose and pre-rescue bronchodilator) forced vital capacity (FVC) after 2, 4 and 8-week treatment periods.", "timeFrame": "At baseline and week 2, 4, 8."}, {"measure": "Mean Changes From Randomisation Baseline in Trough (Morning Pre-dose and Prerescue Bronchodilator) FEF25-75 After 2, 4 and 8-week Treatment Periods", "description": "Mean change from randomization baseline in through (morning pre-dose and pre-rescue bronchodilator) Forced expiratory flow between 25% and 75% of vital capacity (FEF 25-75) after 2, 4 and 8-week treatment periods.", "timeFrame": "At baseline and at week 2, 4 and 8."}, {"measure": "Mean Pre-dose (and Pre-rescue) Peak Expiratory Flow (PEF) as Assessed Via Asthma Monitor (AM2+) in the Morning and Evening, of the Last Week of the 8-week Treatment Period", "description": "Mean pre-dose (and pre-rescue) peak expiratory flow (PEF) as assessed via asthma monitor (AM2+) in the morning and evening of the last week of the 8-week treatment period.", "timeFrame": "At week 8."}, {"measure": "Mean Rescue Medication Use (Daytime and Night-time) as Assessed Via Asthma Monitor (AM2+) in the Morning and Evening, of the Last Week of the 8-week Treatment Period", "description": "Mean rescue medication use (daytime and night-time) as assessed via asthma monitor (AM2+) in the morning and evening, of the last week of the 8-week treatment period.", "timeFrame": "At week 8."}, {"measure": "Mean Change From Randomisation Baseline in Asthma Control Questionnaire (ACQ-6) Scores at Subsequent Study Visits", "description": "The Asthma Control Questionnaire (ACQ) consists of 6 patient self-evaluated questions with each question in 7-point scale. The items are equally weighted and the ACQ score is the mean of 6 items and ranges between 0 (well controlled) and 6 (extremely poorly controlled). Mean scores of less than or equal to 0.75 indicate well-controlled asthma, scores between 0.76 and less than 1.5 indicate partly controlled asthma, and a score greater than or equal to 1.5 indicates uncontrolled asthma.", "timeFrame": "At baseline and at week 2, 4 and 8."}, {"measure": "Mean Change From Randomisation Baseline in Asthma Quality of Life Questionnaire (AQLQ(S)+12) Scores at Subsequent Study Visits", "description": "AQLQ(S)+12 are well established and validated questionnaires to measure control of asthma symptoms and quality of life, which is a patient-reported self-administered outcome questionnaire containing 32 items. Each item is scored on a 7-point scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "timeFrame": "At baseline and at week 2, 4 and 8."}, {"measure": "Time to Withdrawal Due to First Asthma Exacerbation", "description": "Time to withdrawal due to first asthma exacerbation.", "timeFrame": "At week 8."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Male and female patients aged at least 12 to 65 years\n2. All patients must have a history of asthma diagnosed by a physician for at least three months at the time of enrolment into the trial according to the 2009 Global Initiative for Asthma (GINA) Guidelines. The initial diagnosis of asthma must have been made before the age of 40 years 4 All patients must be on a maintenance treatment with either low-dose inhaled corticosteroid (ICS) plus long-acting-beta -agonist (LABA) or medium-dose ICS without LABA, stable for at least six weeks prior to Visit 1\n\n5 All patients must have a pre-bronchodilator FEV1 of not less than 60 to 90% of predicted normal and an asthma control questionnaire (ACQ-6) mean score of less than 1.5 at the pre-screening Visit 1 6 All patients must have an improvement in forced expiratory volume in one second (FEV1) not less than 12 % above baseline and an absolute change of at least 200 mL within 15-30 min after administration of 400 mcg salbutamol/albuterol hydrofluoroalkane metered dose inhaler (HFA MDI) 7 Patients must be never-smokers or ex-smokers with a smoking history of less than 10 pack-years and smoking cessation at least one year prior to screening 9 Patients must be able to use Respimat\u00ae inhaler and metered dose inhaler (MDI) correctly 10 Patients must be able to perform all trial-related procedures including technically acceptable pulmonary function tests and electronic peak expiratory flow (PEF) measurements, and must be able to maintain records during the study period as required in the protocol\n\nExclusion criteria:\n\n1. Patients with significant pulmonary disease other than asthma or other significant medical conditions (as determined by medical history, examination and clinical investigations at screening)\n2. Patients with a clinically relevant, abnormal screening haematology and/or blood chemistry finding\n3. Patients with a history of upper or lower respiratory tract infection (URTI/LRTI) in the past four weeks prior to the pre-screening Visit 1, and during pre-screening and run-in periods\n4. Patients with any exacerbation of their underlying asthma during the eight weeks prior to the pre-screening Visit 1\n5. Patients with active allergic rhinitis requiring treatment with systemic corticosteroids\n6. Any of the following criteria are met during the pre-screening / run-in period (Visits 1 - 6):in clinic pre-bronchodilator forced expiratory volume in one second (FEV1 %) predicted less than 40%; more than 12 puffs rescue salbutamol/albuterol HFA MDI per day for \\> 2 consecutive days;exacerbation of asthma\n7. Patients with a history of pneumonectomy or who are planning to undergo thoracotomy for any reason\n8. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the six weeks prior to the first screening visit 1\n9. Patients with two or more hospitalizations for asthma within the previous 12 months\n10. Patients with a recent history of myocardial infarction during the last twelve months or known coronary heart disease that requires treatment\n11. Patients with a history of hospitalisation due to heart failure in the past twelve months\n12. Patients with myocarditis or any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year\n13. Patients with significant alcohol or drug abuse in the opinion of the investigator within the past two years\n14. Patients with rheumatoid arthritis or other systemic diseases that require immune system modulating treatment\n15. Patients suffering from narrow angle glaucoma with a history of glaucoma, increased intraocular pressure, and/or cataracts\n16. Pregnant or nursing women\n17. Women of childbearing potential not using a highly effective method of birth control\n18. Patients who have been treated with anti-Immunoglobin-E-antibodies (e.g. omalizumab, Xolair\u00ae) or other immune system modulating antibodies such as tumor necrosis factor-alpha blockers within six months prior to Visit 1\n19. Patients who have been treated with the following drugs during the past four weeks prior to Visit 1 or are foreseen to need this during the study:Non-selective beta-blockers (topical cardio-selective beta-blocker eye medications for non-narrow angle glaucoma are allowed; Oral or other systemic corticosteroids; Oral beta-agonists; Changes in allergen desensitisation therapy in last 6 months; Immune system modulating agents such as methotrexate or cyclosporine; Inhibitors of cytochrome P450 3A4 such as antifungals (e.g. ketoconazole, itraconazole), antibiotics (e.g. erythromycin) or antiretroviral drugs; Patients who have been treated with leukotriene modifiers, chromones or theophylline within two weeks prior to Visit 1; Patients who have been treated with tiotropium within 3 weeks prior to Visit 1", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1248.5.01047 Boehringer Ingelheim Investigational Site", "city": "Fountain Valley", "state": "California", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "1248.5.01041 Boehringer Ingelheim Investigational Site", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "1248.5.01038 Boehringer Ingelheim Investigational Site", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "1248.5.01004 Boehringer Ingelheim Investigational Site", "city": "Mission Viejo", "state": "California", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "1248.5.01028 Boehringer Ingelheim Investigational Site", "city": "Palmdale", "state": "California", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "1248.5.01014 Boehringer Ingelheim Investigational Site", "city": "Rancho Mirage", "state": "California", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "1248.5.01044 Boehringer Ingelheim Investigational Site", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "1248.5.01015 Boehringer Ingelheim Investigational Site", "city": "Centennial", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "1248.5.01022 Boehringer Ingelheim Investigational Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "1248.5.01042 Boehringer Ingelheim Investigational Site", "city": "Sarasota", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "1248.5.01051 Boehringer Ingelheim Investigational Site", "city": "Columbus", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "1248.5.01052 Boehringer Ingelheim Investigational Site", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "1248.5.01011 Boehringer Ingelheim Investigational Site", "city": "Eagle", "state": "Idaho", "country": "United States", "geoPoint": {"lat": 43.69544, "lon": -116.35401}}, {"facility": "1248.5.01055 Boehringer Ingelheim Investigational Site", "city": "Oak Lawn", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.71087, "lon": -87.75811}}, {"facility": "1248.5.01019 Boehringer Ingelheim Investigational Site", "city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "1248.5.01039 Boehringer Ingelheim Investigational Site", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "1248.5.01037 Boehringer Ingelheim Investigational Site", "city": "Ypsilanti", "state": "Michigan", "country": "United States", "geoPoint": {"lat": 42.24115, "lon": -83.61299}}, {"facility": "1248.5.01056 Boehringer Ingelheim Investigational Site", "city": "Rolla", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "1248.5.01036 Boehringer Ingelheim Investigational Site", "city": "Warrensburg", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.76279, "lon": -93.73605}}, {"facility": "1248.5.01020 Boehringer Ingelheim Investigational Site", "city": "Omaha", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "1248.5.01049 Boehringer Ingelheim Investigational Site", "city": "Berlin", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 39.79123, "lon": -74.92905}}, {"facility": "1248.5.01054 Boehringer Ingelheim Investigational Site", "city": "Trenton", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.21705, "lon": -74.74294}}, {"facility": "1248.5.01010 Boehringer Ingelheim Investigational Site", "city": "Verona", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.82982, "lon": -74.24015}}, {"facility": "1248.5.01006 Boehringer Ingelheim Investigational Site", "city": "Rochester", "state": "New York", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "1248.5.01031 Boehringer Ingelheim Investigational Site", "city": "High Point", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "1248.5.01045 Boehringer Ingelheim Investigational Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "1248.5.01005 Boehringer Ingelheim Investigational Site", "city": "Gresham", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.49818, "lon": -122.43148}}, {"facility": "1248.5.01021 Boehringer Ingelheim Investigational Site", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "1248.5.01013 Boehringer Ingelheim Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "1248.5.01040 Boehringer Ingelheim Investigational Site", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "1248.5.01012 Boehringer Ingelheim Investigational Site", "city": "Upland", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "1248.5.01048 Boehringer Ingelheim Investigational Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "1248.5.01050 Boehringer Ingelheim Investigational Site", "city": "Austin", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "1248.5.01002 Boehringer Ingelheim Investigational Site", "city": "Live Oak", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.56523, "lon": -98.3364}}, {"facility": "1248.5.01032 Boehringer Ingelheim Investigational Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "1248.5.01046 Boehringer Ingelheim Investigational Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "1248.5.01001 Boehringer Ingelheim Investigational Site", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "1248.5.01007 Boehringer Ingelheim Investigational Site", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "1248.5.01025 Boehringer Ingelheim Investigational Site", "city": "Murray", "state": "Utah", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "1248.5.01053 Boehringer Ingelheim Investigational Site", "city": "Alexandria", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.80484, "lon": -77.04692}}, {"facility": "1248.5.01030 Boehringer Ingelheim Investigational Site", "city": "Tacoma", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "http://www.mystudywindow.com/"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria.\n\nSubjects were not to be allocated to a treatment group if any of the entry criteria were violated.", "recruitmentDetails": "Randomised, double-blind, double-dummy, Placebo, parallel group study to assess and compare efficacy and safety on an 8-week Treatment with BI 54903 administered via Respimat\u00ae inhaler and fluticasone propionate Hydrofluoralkane Metered dose inhaler in patients with asthma.", "groups": [{"id": "FG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "FG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "FG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "FG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "FG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Not yet defined", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All patients that were randomised and treated with at least one dose of study drug.", "groups": [{"id": "BG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "BG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "BG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "BG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "BG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "29"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.8", "spread": "12.1"}, {"groupId": "BG001", "value": "47.8", "spread": "20.4"}, {"groupId": "BG002", "value": "32.0", "spread": "14.6"}, {"groupId": "BG003", "value": "39.0", "spread": "14.1"}, {"groupId": "BG004", "value": "41.5", "spread": "14.5"}, {"groupId": "BG005", "value": "40.6", "spread": "14.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "16"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "13"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "6"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "4"}, {"groupId": "BG005", "value": "23"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "27"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From the Randomisation Baseline to the End of the 8-week Treatment Period in Trough (Morning Pre-dose and Pre-rescue Bronchodilator ) Forced Expiratory Volume in One Second (FEV1)", "description": "Mean change from the randomisation baseline to the end of the 8-week treatment period in trough (morning pre-dose and pre-rescue bronchodilator ) forced expiratory volume in one second (FEV1).", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At baseline and week 8.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Changes From Randomisation Baseline in Trough (Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in One Second (FEV1) After 2 and 4-week Treatment Periods", "description": "Mean changes from randomisation baseline in trough (pre-dose and pre-rescue bronchodilator) forced expiratory volume in one second (FEV1) after 2 and 4-week treatment periods.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At baseline and at week 2 and 4.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Changes From Randomisation Baseline in Trough (Pre-dose and Pre-rescue Bronchodilator) Forced Vital Capacity (FVC) After 2, 4 and 8-week Treatment Periods", "description": "Mean changes from randomisation baseline in trough (pre-dose and pre-rescue bronchodilator) forced vital capacity (FVC) after 2, 4 and 8-week treatment periods.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At baseline and week 2, 4, 8.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Changes From Randomisation Baseline in Trough (Morning Pre-dose and Prerescue Bronchodilator) FEF25-75 After 2, 4 and 8-week Treatment Periods", "description": "Mean change from randomization baseline in through (morning pre-dose and pre-rescue bronchodilator) Forced expiratory flow between 25% and 75% of vital capacity (FEF 25-75) after 2, 4 and 8-week treatment periods.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At baseline and at week 2, 4 and 8.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Pre-dose (and Pre-rescue) Peak Expiratory Flow (PEF) as Assessed Via Asthma Monitor (AM2+) in the Morning and Evening, of the Last Week of the 8-week Treatment Period", "description": "Mean pre-dose (and pre-rescue) peak expiratory flow (PEF) as assessed via asthma monitor (AM2+) in the morning and evening of the last week of the 8-week treatment period.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At week 8.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Rescue Medication Use (Daytime and Night-time) as Assessed Via Asthma Monitor (AM2+) in the Morning and Evening, of the Last Week of the 8-week Treatment Period", "description": "Mean rescue medication use (daytime and night-time) as assessed via asthma monitor (AM2+) in the morning and evening, of the last week of the 8-week treatment period.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At week 8.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation Baseline in Asthma Control Questionnaire (ACQ-6) Scores at Subsequent Study Visits", "description": "The Asthma Control Questionnaire (ACQ) consists of 6 patient self-evaluated questions with each question in 7-point scale. The items are equally weighted and the ACQ score is the mean of 6 items and ranges between 0 (well controlled) and 6 (extremely poorly controlled). Mean scores of less than or equal to 0.75 indicate well-controlled asthma, scores between 0.76 and less than 1.5 indicate partly controlled asthma, and a score greater than or equal to 1.5 indicates uncontrolled asthma.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At baseline and at week 2, 4 and 8.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation Baseline in Asthma Quality of Life Questionnaire (AQLQ(S)+12) Scores at Subsequent Study Visits", "description": "AQLQ(S)+12 are well established and validated questionnaires to measure control of asthma symptoms and quality of life, which is a patient-reported self-administered outcome questionnaire containing 32 items. Each item is scored on a 7-point scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At baseline and at week 2, 4 and 8.", "groups": [{"id": "OG000", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG001", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}, {"id": "OG004", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Time to Withdrawal Due to First Asthma Exacerbation", "description": "Time to withdrawal due to first asthma exacerbation.", "populationDescription": "Study was terminated by the decision of sponsor. No valid data for primary and secondary endpoints were collected and no analyses of primary and secondary endpoints were conducted.", "reportingStatus": "POSTED", "timeFrame": "At week 8.", "groups": [{"id": "OG000", "title": "Placebo HFA MDI", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler)."}, {"id": "OG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks."}, {"id": "OG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks."}, {"id": "OG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From randomization until 8 weeks at end of trial + 2 weeks of follow-up period, up to 10 weeks.", "description": "The treated sets consists of all randomized patients where at least one dose of study medication was taken.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Oral inhalation from Hydrofluoralkane (HFA) Metered dose inhaler (MDI) (combined with placebo Respimat\u00ae inhaler.)", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 3, "otherNumAtRisk": 8}, {"id": "EG001", "title": "BI 54903 22.7\u00b5g Bid", "description": "2 puffs of 11.4 microgram (\u00b5g) (total 22.7 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 5, "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 0, "otherNumAtRisk": 5}, {"id": "EG002", "title": "BI 54903 45.5\u00b5g Bid", "description": "2 puffs of 22.7 microgram (\u00b5g) (total 45.5 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) b.i.d.) for a treatment period of 8 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}, {"id": "EG003", "title": "BI 54903 90.9\u00b5g Bid", "description": "2 puffs of 45.5 microgram (\u00b5g) (total 90.9 \u00b5g) of BI 54903 ethanolic solution for inhalation were inhaled orally twice daily (bid), in the morning and evening via Respimat\u00ae inhaler (combined with 2 puffs placebo Hydrofluoralkane (HFA) Metered dose inhaler (MDI) bid) for a treatment period of 8 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 1, "otherNumAtRisk": 6}, {"id": "EG004", "title": "Fluticasone Propionate 88\u00b5g Bid", "description": "2 puffs of 44 \u00b5g (total 88 \u00b5g) Fluticasone propionate were orally administered twice daily (bid) via Hydrofluoralkane (HFA) Metered dose inhaler (MDI), combined with placebo Respimat\u00ae inhaler.", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 0, "otherNumAtRisk": 6}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 6}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 6}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Study was terminated by the decision of the sponsor. As limited data were collected due to early termination and only limited number of patients completed the 8-week treatment period, no analyses of primary and secondary endpoints were conducted."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.\n\nInvestigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.\n\nBI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Bulgaria", "Czech Republic", "Germany", "Israel", "Korea, Republic of", "Mexico", "Poland", "Slovakia", "South Africa"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}